VEO Ophthalmics’ Artificial Iris, Boston Scientific’s Single-Use Duodenoscope Win Pass-Through Payments
US CMS described several products winning device pass-through payment status for 2021 in an outpatient prospective payment system final rule.
You may also be interested in...
The funds will support expanded commercialization of the company’s baroreflex activation stimulation technology to treat heart failure in patients with a low left-ventricular ejection fraction.
The Centers for Medicare and Medicaid Services highlighted three FDA breakthrough devices it is proposing for additional pass-through payments in its 2021 outpatient pay rule.
Amid concerns of infections from duodenoscopes that are not sufficiently re-sterilized, the US FDA has cleared Boston Scientific’s Exalt-D as a the first single-use duodenoscope. Investors expect the device will likely take a significant chunk of the market, especially considering the next competitor is at least a year away.